• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Richard Pazdur

Richard Pazdur
Favicon Fierce Pharma

FDA names oncology vet Pazdur as new CDER director

Richard Pazdur, M.D., who has been with the FDA for 26 years, will lead CDER.
Angus Liu Nov 11, 2025 5:18pm
Richard Pazdur

FDA's Richard Pazdur explains confirmatory trial rejection, more

Apr 8, 2024 6:00am
Richard Pazdur

FDA looks to bypass cancer drugs' companion diagnostics: Pazdur

Nov 18, 2022 9:17am
Pazdur

Follow-up trials should be underway for accelerated nods: Pazdur

Nov 17, 2022 3:36pm
robert Califf swearing in FDA commissioner

Califf backs cancer czar's proposal to limit single-arm trials

Jul 29, 2022 11:33am
Drug inspection FDA regulatory submission

BIO chair mounts defense against accelerated approval reforms

Jun 28, 2022 10:40am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings